@article{2e6b2173c7984887b40321946dbc3a59,
title = "The GPR139 agonist TAK-041 produces time-dependent alterations to cerebral blood flow and reward system function in patients with schizophrenia",
author = "Peter Hawkins and James Gilleen and Mitul Mehta",
note = "This work represents a *First In Patient* drug study of a novel compound to improve negative symptoms of schizophrenia. Improving negative symptoms is a major unmet clinical need and development of efficacious pharmacological strategies has eluded Pharma and Academia to date. This study maps neatly on to a Translational Psychiatry pathway deriving from work in experimental animals. The study shows, for the first time, that this compound may be able to improve negative symptoms in schizophrenia - and so has considerable potential for impact. We are working on a follow-up study.",
year = "2021",
month = mar,
day = "13",
language = "English",
journal = "NEUROPSYCHOPHARMACOLOGY",
issn = "0893-133X",
publisher = "Nature Publishing Group",
}